<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802070</url>
  </required_header>
  <id_info>
    <org_study_id>C.A.S.T.</org_study_id>
    <nct_id>NCT04802070</nct_id>
  </id_info>
  <brief_title>Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.</brief_title>
  <official_title>A Phase I Study of Adoptive Immunotherapy With Cytokine-Induced Killer Cells in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Franca Fagioli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monocentric, phase I study for advanced sarcoma with adoptive immunotherapy with&#xD;
      Cytokine-Induced Killer (CIK).&#xD;
&#xD;
      In the first part of the study Patient's' peripheral blood will be collected and CIK cell&#xD;
      expansion and storage will occur at the Regina Margherita Children's Hospital Cell Factory.&#xD;
&#xD;
      In the second part of the study the Maximum Tolerated Dose (MTD) will be determined in order&#xD;
      to find the Recommended Dose for Phase II (RP2D)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>6 weeks</time_frame>
    <description>Incidence of dose-limiting toxicity (DLT) associated with CIK autologous cells administration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>CIK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous CIK</intervention_name>
    <description>Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)</description>
    <arm_group_label>CIK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for part 1&#xD;
&#xD;
          -  Patients with histologically documented unresectable sarcomas which progressed after&#xD;
             first or further line treatments for relapsing disease who could be enrolled in Part 2&#xD;
             of study immediately or after a new line of treatment;&#xD;
&#xD;
          -  Karnofsky score ≥ 70% (patients with Karnofsky score ≥ 50% are eligible if it depends&#xD;
             solely on orthopedic problems)&#xD;
&#xD;
          -  Estimated life expectancy &gt; 3 months;&#xD;
&#xD;
          -  Adequate bone marrow functions:&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
          -  Negative serum or urine pregnancy test within 48 hours from collection of peripheral&#xD;
             blood or from lympho cyto apheresis (if post-pubertal female patients);&#xD;
&#xD;
          -  Archived histological tumour sample available&#xD;
&#xD;
        Inclusion Criteria for part 2&#xD;
&#xD;
          -  Patients with histologically documented unresectable sarcomas which progressed after a&#xD;
             first or further line treatments for relapsing disease&#xD;
&#xD;
          -  Measurable disease (bone lesions are included);&#xD;
&#xD;
          -  Karnofsky score ≥ 70% (patients with Karnofsky score ≥ 50% are eligible if its depend&#xD;
             solely on orthopedic problems)&#xD;
&#xD;
          -  Estimated life expectancy &gt; 3 months;&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal functionality&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
          -  Archived histological tumour sample available;&#xD;
&#xD;
          -  Patients should have a venous central access;&#xD;
&#xD;
          -  Pregnancy test should be negative 48 hours before treatment for post-pubertal women&#xD;
             patients. All post-pubertal patients are to take adequate anti-contraceptive measures&#xD;
             during treatment and until 8 weeks after the last dose of treatment.&#xD;
&#xD;
        Exclusion Criteria for part 1&#xD;
&#xD;
          -  History of Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus or&#xD;
             Hepatitis A Virus infection;&#xD;
&#xD;
          -  Patients receiving chemotherapy and/or immunotherapy and/or anti-tumour agents and/or&#xD;
             radiotherapy on more than 10% of bone marrow area two weeks before peripheral blood&#xD;
             collection or lymphocytapheresis;&#xD;
&#xD;
          -  Patients with neuro-psychiatric disorders or social or geographic problems that would&#xD;
             prohibit the understanding or rendering informed consent and compliance with the&#xD;
             requirements of this protocol are excluded.&#xD;
&#xD;
        Exclusion Criteria for part 2&#xD;
&#xD;
          -  Patients with Ewing/Primitive Neuroectodermal Tumor Sarcoma, Rhabdomyosarcoma as well&#xD;
             as other rapidly growing sarcomas are not to be included in the study;&#xD;
&#xD;
          -  Presence of Central Nervous System metastases and/or meningeal neoplastic involvement;&#xD;
&#xD;
          -  Patients with seizure disorders;&#xD;
&#xD;
          -  Severe renal, vascular, cardiac, hepatic, lung disorders;&#xD;
&#xD;
          -  Patients with any severe and/or uncontrolled medical conditions such as unstable&#xD;
             angina pectoris, heart failure ≥ grade 2, a recent heart attack within 6 months,&#xD;
             uncontrolled heart non arrhythmia uncontrolled metabolic disorders, cirrhosis,&#xD;
             uncontrolled hypertension&#xD;
&#xD;
          -  Patients with a non-optimal ex-vivo expansion of autologous CIK cells during Part 1 (&lt;&#xD;
             0.5 x 107/kg CIK cells);&#xD;
&#xD;
          -  History of Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus or&#xD;
             Hepatitis A Virus infection;&#xD;
&#xD;
          -  Presence of bleeding disorders;&#xD;
&#xD;
          -  Patients undergoing renal dialysis;&#xD;
&#xD;
          -  Presence of uncontrolled diabetes&#xD;
&#xD;
          -  Patients unable to swallow oral medications;&#xD;
&#xD;
          -  Patients receiving concomitant steroid or immunotherapy (except corticosteroids with a&#xD;
             daily dosage equivalent to prednisone ≤ 20 mg for adrenal insufficiency).&#xD;
&#xD;
          -  Anticancer chemotherapy or experimental drugs or immunotherapy or radiotherapy 2 weeks&#xD;
             before entering the study;&#xD;
&#xD;
          -  Anticancer chemotherapy or experimental drugs or immunotherapy or radiotherapy on&#xD;
             target lesions 2 weeks before entering the study;&#xD;
&#xD;
          -  Prior exposure to CIK cells;&#xD;
&#xD;
          -  Major surgery 4 weeks before entering the study;&#xD;
&#xD;
          -  Minor surgery 1 week before entering the study;&#xD;
&#xD;
          -  Patients with allergic reactions or hypersensibility to excipient&#xD;
&#xD;
          -  Pregnant or breast-feeding patients;&#xD;
&#xD;
          -  Patients with neuro-psychiatric disorders or social or geographic problems that would&#xD;
             prohibit the understanding or rendering of informed consent and compliance with the&#xD;
             requirements of this protocol are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Franca Fagioli, MD</last_name>
    <phone>00390113135997</phone>
    <email>franca.fagioli@unito.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD</last_name>
      <phone>0039011313</phone>
      <phone_ext>5997</phone_ext>
      <email>franca.fagioli@unito.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</investigator_affiliation>
    <investigator_full_name>Prof. Franca Fagioli</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

